NCT06992180

Brief Summary

This randomized controlled trial aims to evaluate the effectiveness of an AI-based mental health chatbot, Emohaa, in reducing symptoms of depression, anxiety, insomnia, and academic burnout among young adults experiencing emotional distress. A total of 222 participants will be randomly assigned to one of three groups: (1) AI chatbot intervention, (2) traditional counseling, or (3) waitlist control. The study spans six time points from baseline through one-month follow-up. Primary and secondary outcomes will be measured via validated self-report questionnaires. The intervention is delivered entirely online through a WeChat-integrated platform, ensuring high accessibility and scalability.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
222

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2025

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 18, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

May 20, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 28, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2025

Completed
11 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 10, 2025

Completed
Last Updated

May 28, 2025

Status Verified

May 1, 2025

Enrollment Period

3 months

First QC Date

May 18, 2025

Last Update Submit

May 24, 2025

Conditions

Keywords

Depressionanxiety

Outcome Measures

Primary Outcomes (2)

  • Depression

    The Patient Health Questionnaire-9 (PHQ-9) was employed in this study to measure depressive symptoms. This scale consists of 9 items, each rated on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, with scores of 0-4 indicating no depressive symptoms, 5-9 indicating mild symptoms, 10-14 indicating moderate symptoms, and 15 or above indicating severe depressive symptoms. Previous research has demonstrated good reliability and validity for the Chinese version of the PHQ-9.

    From enrollment to the end of treatment at 10 weeks

  • Anxiety

    The Generalized Anxiety Disorder-7 (GAD-7) was used to assess anxiety symptoms in this study. This scale consists of 7 items, each rated on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 21, with scores of 0-4 indicating no anxiety symptoms, 5-9 indicating mild symptoms, 10-14 indicating moderate symptoms, and 15 or above indicating severe anxiety symptoms. Prior studies have shown that the Chinese version of the GAD-7 has good reliability and validity.

    From enrollment to the end of treatment at 10 weeks

Secondary Outcomes (1)

  • Loneliness

    From enrollment to the end of treatment at 10 weeks

Other Outcomes (1)

  • Satisfaction with the GAI intervention

    From first GAI intervention to the end of treatment at 10 weeks

Study Arms (3)

Generative Artificial Intelligence Intervention Group

EXPERIMENTAL

Participants will interact weekly with Emohaa via a WeChat-integrated interface for 30-minute sessions over a 6-week period. The chatbot uses fine-tuned large language models to simulate emotionally supportive conversations and provide personalized, non-directive psychological support.

Behavioral: Generative Artificial Intelligence Intervention

Individual Psychological Counseling Group

EXPERIMENTAL

Participants will receive six weekly sessions (face-to-face or remote) with trained counselors using structured, supportive counseling protocols derived from cognitive-behavioral therapy (CBT).

Behavioral: Individual Psychological Counseling

Waiting List Group

NO INTERVENTION

Participants will not receive any intervention during the study period but will be offered access to Emohaa after study completion.

Interventions

The intervention is delivered via a generative artificial intelligence platform called Emohaa. Participants will register and gain access to the platform prior to the start of the trial. Emohaa's responses are based on Hill's helping skills theory in psychology and are designed to simulate the basic communication strategies of a human counselor. The system demonstrates strong capabilities in active listening, emotional mirroring, and empathy, supporting users in understanding their own thoughts and feelings, learning to cope with emotional challenges, and achieving a more optimistic and positive mental and emotional state.

Generative Artificial Intelligence Intervention Group

Participants in the traditional counseling group will receive individual psychological counseling sessions conducted by certified psychotherapists.

Individual Psychological Counseling Group

Eligibility Criteria

Age15 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age ranges from 15 to 30
  • Suffering from emotional distress (PHQ-9 \> 14 or GAD-7 \> 12)
  • Ability to use the mobile phone to interact with AI
  • Consent to participate in the study

You may not qualify if:

  • High risk of self-injury and suicide
  • Presence of psychotic symptoms (i.e., delusions)
  • Serious substance use problems
  • Other mental or physical illnesses requiring urgent medical assistance
  • Received other psychological or pharmacological interventions in the last month.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

DepressionAnxiety Disorders

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorMental Disorders

Study Officials

  • Zhihong Qiao, Doctor

    Beijing Normal University

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate researcher

Study Record Dates

First Submitted

May 18, 2025

First Posted

May 28, 2025

Study Start

May 20, 2025

Primary Completion

August 30, 2025

Study Completion

September 10, 2025

Last Updated

May 28, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will share

We will release the statistical analysis results based on the research design after anonymizing the personal identification information of the participants. And the raw data of each participant can be obtained through the corresponding author of the research report.